Pharmaceutical Executive

Pharmaceutical Executive Podcast
  • 4,0 (2)
  • SCIENCE DE LA VIE
  • TOUS LES JOURS

The Pharm Exec Podcast goes beyond the pages of the Pharmaceutical Executive print magazine and PharmExec.com to bring the latest commercial insights to the C-suite through in-depth interviews. Podcast episodes examine current trends, key conferences, and critical topics in the industry. 

  1. Pharmaceutical Executive Daily: FDA Issues CRL to AbbVie

    -23 H

    Pharmaceutical Executive Daily: FDA Issues CRL to AbbVie

    In today’s Pharmaceutical Executive Daily, the FDA issues a complete response letter to AbbVie for a biologics license application, Regeneron moves to lower patient costs tied to its newly approved gene therapy, and the FDA approves Otarmeni for OTOF-related hearing loss.

    2 min
  2. Pharmaceutical Executive Daily: FDA Expands Approvals for Tzield and Dupixent

    -1 J

    Pharmaceutical Executive Daily: FDA Expands Approvals for Tzield and Dupixent

    In today’s Pharmaceutical Executive Daily, the FDA expands the use of Tzield to young children to delay the onset of stage 3 type 1 diabetes, Dupixent receives an expanded pediatric indication in chronic spontaneous urticaria, and AbbVie announces a $195 million investment to build a new manufacturing campus in North Carolina.

    2 min
  3. The Ron Lanton Report: Where Innovations Happens

    -1 J

    The Ron Lanton Report: Where Innovations Happens

    In this episode, Ron Lanton examines how geography is becoming a central strategic variable in healthcare, as policy, trade dynamics, and infrastructure increasingly dictate where innovation is developed, manufactured, and commercialized.

    9 min
  4. Pharmaceutical Executive Daily: Idvynso Receives FDA Approval

    -2 J

    Pharmaceutical Executive Daily: Idvynso Receives FDA Approval

    In today’s Pharmaceutical Executive Daily, the FDA approves a new treatment for HIV-1 infection in adults, Amazon One Medical launches a GLP-1 weight management program, and a new report highlights which top-selling drugs are most at risk of supply shortages.

    2 min
  5. Pharmaceutical Executive Daily: UnitedHealth Raises Full-Year Profit Forecast

    -3 J

    Pharmaceutical Executive Daily: UnitedHealth Raises Full-Year Profit Forecast

    In today’s Pharmaceutical Executive Daily, UnitedHealth raises its full-year profit forecast following stronger-than-expected first-quarter results, Pfizer works to reshape its leadership narrative as it approaches a major patent cliff, and a new industry perspective highlights why scaling artificial intelligence in pharma requires more than just advanced algorithms.

    2 min
  6. Pharmaceutical Executive Daily: Eli Lilly Acquires Kelonia Therapeutics

    -4 J

    Pharmaceutical Executive Daily: Eli Lilly Acquires Kelonia Therapeutics

    In today’s Pharmaceutical Executive Daily, Eli Lilly enters a $7 billion agreement to acquire Kelonia Therapeutics, the Trump administration issues an executive order to accelerate FDA reviews of psychedelic therapies, and Lilly’s oral weight loss pill sees strong early prescribing demand.

    2 min
  7. Inside Pharma's Revenue Engine: The Gross-to-Net Reckoning

    17 AVR.

    Inside Pharma's Revenue Engine: The Gross-to-Net Reckoning

    In the debut episode of Pricing & Policy with Model N — a new podcast series from Pharmaceutical Executive — Model N VP of product management Michael Grosberg joins host Mike Christel to break down what the company's annual state of revenue survey reveals about the mounting pressures threatening pharma's commercial foundation. From PBM opacity and Medicaid withdrawal to "ghost claims" lurking inside DTC channels, this conversation pulls back the curtain on the industry's most consequential — and perhaps least understood — business challenge: revenue management. 01:50 - Drivers of rising GTN complexity. 05:08 - The Medicaid dilemma: Exiting the program. 08:30 - Coordination of benefits and rebate eligibility: “We’re doing a really poor job at this.” 10:57 - The easiest way to solve the problem.  12:04 - IRA’s Medicare drug price negotiations: Where we stand. 16:20 - Launch strategy and sequencing considerations. 20:13 - MFN agreements transparency.  21:51 - Data disconnect blurs pricing and revenue visibility. 24:05 - AI "catch-up" imperatives for revenue management. 27:48 - System strain? DTC’s downstream impacts. 33:36 - Top threats to future model.

    37 min
  8. Pharmaceutical Executive Daily: Eli Lilly Releases Updated Safety Data for Foundayo

    16 AVR.

    Pharmaceutical Executive Daily: Eli Lilly Releases Updated Safety Data for Foundayo

    In today's Pharmaceutical Executive Daily, Eli Lilly releases updated safety data for its oral obesity pill Foundayo in response to an FDA post-approval request, ICER and Verdant Research publish a new white paper examining the evolution and future of the FDA's accelerated approval pathway, and a new Pharmaceutical Executive commentary argues FDA's shift toward single-trial approval standards marks the beginning of a genuinely new era in data-driven drug development.

    3 min
Tout afficher (341)

Notes et avis

4
sur 5
2 notes

À propos

The Pharm Exec Podcast goes beyond the pages of the Pharmaceutical Executive print magazine and PharmExec.com to bring the latest commercial insights to the C-suite through in-depth interviews. Podcast episodes examine current trends, key conferences, and critical topics in the industry. 

Informations

  • Créateur
    Pharmaceutical Executive Podcast
  • Années d’activité
    2018 - 2026
  • Épisodes
    341
  • Classement
    Tout public
  • Site Web de l’émission
    Pharmaceutical Executive

Vous aimerez peut-être aussi